The mechanism gets flattened
“Growth hormone release” is not enough to explain pulsatility, feedback or why timing matters.
Free webinar · For medical professionalsTesamorelin:
Dr. Greg Jones, NMDEnovative Wellness · ISSCA faculty
Tesamorelin:
Mechanisms &
Clinical Application
Go from GHRH receptor biology to patient selection, dosing, monitoring and the clinical judgement that sits between them.
DosingProtocolsFrameworks
Included free. Download the clinical materials as they unlock during the session.
Dr. Greg Jones, NMDEnovative Wellness · ISSCA facultyHelped 100 physicians through ISSCA training.
24:47focused session
Practitioner-ledclinical context
Evidence-awarescope & caveats
Interactivechecks & resources
Sound familiar?You know the peptide.
01 02 03
You know the peptide.
But can you defend the protocol?
Trial dosing becomes dogma
Research protocols and clinical practice are repeated as if they are the same decision.
Monitoring starts too late
IGF-1, glycemic markers and patient-specific risk need a baseline, not a rescue plan.
Dr. Jones connects those gaps — from receptor to real-world judgement.
What you’ll walk away withFive clinical takeaways.
01 02 03 04 05
Five clinical takeaways.
One usable framework.
The GHRH pathway
Understand pulsatility, negative feedback and why Tesamorelin behaves differently from ghrelin mimetics and recombinant GH.
Why visceral fat responds
Connect receptor density and lipolytic activity to the effect clinicians should—and should not—promise.
Evidence versus extrapolation
Separate the Phase 3 HIV-lipodystrophy data from off-label clinical use without blurring the line.
Dosing, timing & cycling
Compare studied dosing with the clinician’s practical approach, including the empty-stomach rationale.
Screening & monitoring
Build a baseline around IGF-1, glucose, insulin, HbA1c and lipids, with contraindications kept visible.
Inside the evidenceThe number is useful.
The number is useful.
The caveat is essential.
Dr. Jones reviews the pivotal trials and then puts the result back inside a full clinical protocol.
15–18%visceral fat reduction versus placebo at 26 weeksTwo Phase 3 trials · approximately 800 patients · CT-measured primary endpoint
Your presenter
Dr. Greg Jones, NMD
Enovative Wellness · ISSCA Global Summit faculty
A practitioner-led session built around the questions that change patient selection and protocol design: mechanism, dose, timing, monitoring, safety and scope of evidence.
Dr. Jones has personally certified 1,000+ physicians with ISSCA.
“The value is not knowing one peptide. It is knowing what to watch, what to question and when not to proceed.”
Is this for you?Built for clinicians who want
Built for clinicians who want
more than a molecule overview.
This is for you if…
You prescribe—or are evaluating—GH secretagogues
You want a mechanism-first explanation
You need a practical monitoring framework
You value clear limits around off-label evidence
This is not for you if…
×You are seeking personal medical advice
×You want a consumer weight-loss shortcut
×You prefer protocol claims without caveats
×You are not a licensed health professional
A preview of the room
This is how the Global Summit begins.
The same receptor-to-protocol depth, practitioner exchange and clinical judgement—previewed in one free session. The full ISSCA Global Summit takes place in September.
No pitch required. Come for the knowledge.Simple as 1—2—3From registration to
1 2 3
From registration to
clinical clarity.
Reserve
Choose the next session or start on demand. Registration takes seconds.
Watch & respond
Move through Dr. Jones’s talk with short knowledge checks and clinical prompts.
Leave with a framework
Take the mechanism, evidence boundaries and monitoring logic back to your practice.
Your next clinical deep dive
Starts here.
Free. No card. Twenty-four focused minutes.
New sessions every 15 minutes · Watch at your own pace